ライフサイエンスコーパス: vehicle control

1 eoxyguanosine by 61% (P < 0.01 compared with vehicle control).

2 as reduced to 41.8 (6.6) minutes (P =.035 vs vehicle control).

3 mation, and weight loss (36%-53% relative to vehicle control).

4 weeks to induce features of Parkinsonism, or vehicle (control).

5 injected with doxorubicin, 3 mg/kg/week, or vehicle (control).

6 itor to reduce visceral hypersensitivity, or vehicle (control).

7 liance; P < 0.05 compared with untreated and vehicle controls).

8 pendent mice (caffeine 125 mg kg-1 day-1 vs. vehicle controls).

9 g/L) alone (124 +/- 5 mmHg) (P < 0.05 versus vehicle controls).

10 ), scopolamine (5, 25 and 100 mug kg(-1)) or vehicle (controls).

11 stinal inflammation compared with mice given vehicle (controls).

12 d with penicillin-streptomycin (PenStrep) or vehicle control.

13 duction in tumour growth (p = 0.005), 56% of vehicle control.

14 r 4T1 tumors compared to 67NR tumors and the vehicle control.

15 EU, 0.08 EU, and 0.02 EU of endotoxin or the vehicle control.

16 he conjunctiva (P </= 0.05) as compared with vehicle control.

17 aly detection, medical diagnosis and robotic vehicle control.

18 detected in DNFB-treated ears compared with vehicle control.

19 the immunoproteasome inhibitor ONX 0914, or vehicle control.

20 urvival in I-BET151 treated mice compared to vehicle control.

21 ture incubated with each FFA, but not with a vehicle control.

22 Recipient mice were treated with TAK-779 or vehicle control.

23 57-B mice received an antipsychotic agent or vehicle control.

24 L-2 production compared with BMDC exposed to vehicle control.

25 ed with Fancc(-/-) donor cells cultured with vehicle control.

26 ions of the LXR agonists T1317 and GW3965 or vehicle control.

27 1, 3, or 5 nMol/kg of CCK-33, CCK-8, or the vehicle control.

28 ed intravitreal injections of azurocidin and vehicle control.

29 induction of caspase-3 and Bax, compared to vehicle control.

30 groups of 10 ng/d CNTF, 1 ng/d CNTF, and PBS vehicle control.

31 N-S-phenyl-glycine-t-butyl ester (DAPT), or vehicle control.

32 rease caspase-3 activation compared with the vehicle control.

33 ze of adhesions (P < 0.05) compared with the vehicle control.

34 increased adhesion formation compared to the vehicle control.

35 period with melatonin (0.6 mg) or 2% ethanol vehicle control.

36 ient ACI rats were pretreated with M40401 or vehicle control.

37 dine (TFT) and balanced salt solution as the vehicle control.

38 l cell loss relative to animals administered vehicle control.

39 eye and the contralateral eye served as the vehicle control.

40 ated retinal reattachment when compared with vehicle control.

41 either a multiple-dose regimen of TNP-470 or vehicle control.

42 old mice were preincubated with vitamin E or vehicle control.

43 bmissive behavior than did animals receiving vehicle control.

44 an that exhibited by animals that received a vehicle control.

45 esion formation compared to treatment with a vehicle control.

46 d from host mice after treatment with JQ1 or vehicle control.

47 p-aminobenzoate, and escin as compared with vehicle control.

48 about 10 times lower with 10 muM Lat-B than vehicle control.

49 nts compared with those in the COH rats with vehicle control.

50 mice in the corticosterone group relative to vehicle control.

51 pon treatment with ganciclovir, but not with vehicle control.

52 antly above either factor alone as well as a vehicle control.

53 a cells treated with genistein compared with vehicle control.

54 Cells were exposed to teduglutide or vehicle control.

55 direct thrombin inhibitor and compared with vehicle control.

56 flammatory foci per muscle field relative to vehicle control.

57 increase in ppET-1 mRNA content compared to vehicle controls.

58 erage net displacement by >/=80% relative to vehicle controls.

59 wer in Cl-amidine-treated mice compared with vehicle controls.

60 severe histological inflammation compared to vehicle controls.

61 ive and citrullinated epitopes compared with vehicle controls.

62 ic raft cultures compared with the level for vehicle controls.

63 n highly sensitive M229 cells, compared with vehicle controls.

64 rct (% contralateral hemisphere) compared to vehicle controls.

65 at reducing freezing behavior as compared to vehicle controls.

66 fewer conditioned responses than unstressed vehicle controls.

67 atment in all treatment groups compared with vehicle controls.

68 levels within the aortic wall as compared to vehicle controls.

69 etreated with control adenovirus (AdNull) or vehicle controls.

70 sed in rats treated with SC58125 compared to vehicle controls.

71 d with AAV9-MIS, recombinant MIS protein, or vehicle controls.

72 /SS cell lines and patients' PBL compared to vehicle controls.

73 of the I/M ratio and %LN when compared with vehicle controls.

74 at 24 hr, but not 1 week, compared with the vehicle controls.

75 ntries in response to the tone compared with vehicle controls.

76 the medial basal hypothalamus compared with vehicle controls.

77 ra of the aged GDNF recipients compared with vehicle controls.

78 23-fold increase in apoptosis compared with vehicle controls.

79 3 hr to 3 d after injury, compared with the vehicle controls.

80 f both tumor and stromal cells compared with vehicle controls.

81 the number of lung metastases compared with vehicle controls.

82 rporation of anisomycin-treated samples with vehicle controls.

83 content versus unstimulated or time-matched vehicle controls.

84 om 5% at 3 h to 35% at 15 h when compared to vehicle controls.

85 inhibitor showed higher platelet counts than vehicle controls.

86 at twice rheobase compared with neurons from vehicle controls.

87 effect on baseline ED performance in chronic vehicle controls.

88 lly reduce tumor volumes over paclitaxel and vehicle controls.

89 ition that normally promotes cue strategy in vehicle controls.

90 c parameters or cellular localization in the vehicle controls.

91 antly reduced cell death at 48 h compared to vehicle control (0.1% DMSO) when administered 0, 1, 6, a

92 ere perfused with medium containing either a vehicle control (0.1% ethanol [ETH]) or dexamethasone (D

93 -week-old APC(min/+) mice were p.o. fed with vehicle control (0.5% carboxymethyl cellulose and 0.025%

94 daily for 12 days (oral gavage) with either vehicle (control, 0.5% w/v hydroxypropyl-methylcellulose

95 Compared with vehicle controls (1.98 +/- 0.34 ml/min), GFR values were

96 Compared to vehicle controls, 18-MC significantly enhanced the expre

97 (4.2+/-2.2%) as compared to their respective vehicle controls (2.5+/-1.4% and 4.6+/-1%).

98 bits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and

99 our treatment groups (n = 12 per group): (1) vehicle control; (2) 5 mg/kg/day LANZO; (3) 5 mg/kg/day

100 ading with VEGF-A injection when compared to vehicle control (26+/-2 vs. 3+/-1 mum/s, P<0.05).

101 andomly assigned one of four treatments: (1) vehicle control (90% propylene glycol + 10% lactated Rin

102 nonhuman nucleic acids and their respective vehicle controls, a denatured cohesive ophthalmic viscos

103 Compared with vehicle controls, administration of RvE1 resulted in sig

104 ctional deficits compared with corresponding vehicle-controls, after 45 and 60 min of ischemia.

105 e bengal staining compared with NGF, DHA, or vehicle control alone.

106 red to treatment with BB-94, gemcitabine, or vehicle control alone.

107 No reactions to the vehicle control and 3 mg/kg BADGE were observed.

108 gens reduced cell numbers below those of the vehicle control and also activated caspases.

109 Eight sheep received on 2 separate days a vehicle control and incremental intravenous boluses of a

110 vely, relative to the difference between the vehicle control and lean hGCGR mice.

111 D/beige mice receiving systemic rapamycin or vehicle control and were analyzed 21 d later.

112 sleep time, compared with both within-animal vehicle controls and between-animal time-controls.

113 21(waf1) were all decreased when compared to vehicle controls and FVB/N mice.

114 antly greater than the Pre and corresponding vehicle controls and non-responsive neurons.

115 ells (1.40+/-0.02-fold, P<0.01 compared with vehicle control) and an EGFR/HER2 inhibitor blocked this

116 ion (85 and 70%, respectively, compared with vehicle control) and reduced foam cell formation (approx

117 mice were concomitantly treated with DEX (or vehicle control) and Scl-AbI antibody (or isotype-matche

118 ane-targeting control regulator (APT898), or vehicle control, and disease was assessed clinically and

119 erformed on eyes exposed to albumin, protein vehicle control, and the OVDs at these time points.

120 re advanced in Pg-challenged animals than in vehicle control animals and occurred earlier (at 10 week

121 ectrical stimulation in PGi increased ECG in vehicle control animals, but decreased it in estradiol-t

122 Compared with vehicle control animals, peanut recall responses in sple

123 arcinoma by 220 days, compared to 50% in the vehicle control animals.

124 s protein labeling existed in a few cells in vehicle control animals.

125 eated with daily injections of vasostatin or vehicle control at a site between the wounds and the tra

126 uced to 64-fold below the mean viral load in vehicle control at day 24.

127 ation and protein concentration) compared to vehicle controls at the two lower doses, but elevated mo

128 days after cancer cell injection to receive vehicle control, BB-94, gemcitabine, or gemcitabine and

129 % [Restasis, Allergan Inc., Irvine, CA]), or vehicle control BID for 8 weeks.

130 nctival injections of exogenous IFN-gamma or vehicle control (BSA) at days 0, +2, and +4 after DS.

131 microg/kg per day (P: < 0.05) than in saline vehicle controls but was abolished in diabetic rats that

132 in streptozotocin-induced DM or age-matched vehicle controls by whole-cell patch clamp at 5- or 10-w

133 s postponed in dextrose-infused mice (versus vehicle control) by an interval of time comparable to th

134 , 6/8 (75%); EXP3174, 2/8 (25%; p < 0.05 vs. vehicle control); captopril, 7/10 (70%).

135 mice had fewer evoked seizures compared with vehicle controls, coinciding with greater preservation o

136 Dams received cocaine (COC) or vehicle (control, CON) intravenously from gestation day

137 thylprednisolone, 0.05% cyclosporin A, and a vehicle control containing carboxymethylcellulose sodium

138 topical fluorouracil cream, 5% (n = 468), or vehicle control cream (n = 464) to the face and ears twi

139 o apply topical fluorouracil, 5%, cream or a vehicle control cream to the face and ears twice daily f

140 thrombin but not with injection of PBS as a vehicle control, demonstrating the first aptamer-based a

141 Using a cross-over, double-blind, vehicle-controlled design, 22 heroin-dependent and heroi

142 Using a double-blind, randomized, vehicle-controlled design, we examined the effects of ch

143 istically significant difference compared to vehicle control despite tumor volume being reduced to le

144 e treated with phosphate buffered saline (as vehicle control), dexamethasone (as positive control), o

145 ing the first 3 h, mTBI alone, compared with vehicle control, did not alter total distance travelled.

146 en-chest dogs randomized to receive RSR13 or vehicle control during a reversible reduction of left an

147 Nine vehicle control earthworms were sacrificed at days 6 and

148 Term DC cultures were incubated with vehicle (control), estradiol (E2) with or without medrox

149 Cultures of HESCs were treated with vehicle control, estradiol (E(2)), or with medroxyproges

150 w after a 3-minute intracoronary infusion of vehicle control (ethanol) followed by 2-minute intracoro

151 monary reflex, when compared to time-matched vehicle control experiments, intracisternal application

152 50 nl unilateral microinjection of aCSF (the vehicle control) followed by 50 n1 of BMI (1 mM) into th

153 ents to topical 0.1% tretinoin or a matching vehicle control for 1.5-5.5 years.

154 day for 5 days) with famciclovir and topical vehicle control for experimental ultraviolet radiation-i

155 e application of 0.5% ivermectin lotion with vehicle control for the elimination of infestations with

156 tive COX-2 inhibitor parecoxib (25 mg/kg) or vehicle (control) for 7 and 28 days.

157 r =90% purified EPA, DHA, oleic acid (OA) or vehicle control, for 4.5 d.

158 Relative to vehicle controls, GP attenuated several effects of HFD f

159 , 0.5 mg estradiol benzoate (E2; n = 10), or vehicle (control group, CNT; n = 10).

160 this compound (experimental group, n = 6) or vehicle (control group, n = 6) per day for 5.5 weeks.

161 arkably lower incidence of metastasis in the vehicle control group (10% LSF versus 40% HSF).

162 All 3AP treatment groups and the vehicle control group displayed slowing of lick rhythm a

163 showed decreased activity compared with the vehicle control group in response to a low-dose cocaine

164 Relative to the vehicle control group, mice receiving corticosterone had

165 length and branching number relative to the vehicle control group.

166 xpression was significantly less than in the vehicle control group.

167 Each substudy included a contemporaneous vehicle control group.

168 d at a significantly better level than their vehicle control group.

169 r nuclei remained, but in the retinas of the vehicle-control group only 38.0% of these nuclei remaine

170 ol (P<0.001 for each treatment group vs. the vehicle-control group).

171 h of the paromomycin groups and three in the vehicle-control group.

172 equent in the paromomycin groups than in the vehicle-control group.

173 oups were significantly lower as compared to vehicle control groups.

174 ecreased in (+)-JQ1 treated mice compared to vehicle control; however, while the effect was in the sa

175 sulted in decreased tumor volume compared to vehicle control; however, while the effect was in the sa

176 nfiltrated with 0.4 mL ETC-216 (14 mg/mL) or vehicle control immediately before deployment of GFX ste

177 he NHE-1 inhibitor zoniporide (3 mg.kg-1) or vehicle control immediately before starting extracorpore

178 in a lower median disease burden compared to vehicle control in all tissues analyzed, similar to the

179 cation of ivermectin was more effective than vehicle control in eliminating head-louse infestations a

180 ed activated caspase3 staining compared with vehicle control in HCC1954 tumors.

181 s (ERB-041 or WAY-202196) were compared with vehicle control in the murine cecal ligation and punctur

182 MVD was reduced by TNP-470 compared with vehicle control in the V+ tumors, but was unaltered in V

183 improved acquisition of memory compared with vehicle controls in a reference-memory Morris water-maze

184 with the Ox1r antagonist did not differ from vehicle controls in locomotor activity following acute-

185 The high rate of comparisons with vehicle controls in randomized controlled trials that as

186 hod) was only marginally reduced relative to vehicle controls in treated graft recipients.

187 rall survival vs. mice treated with dEpoB or vehicle control, indicating that Flu may be a promising

188 Relative to vehicle controls, infusion of U0126 impaired training-in

189 ceived either 15 microg of GLP-1 I.V.T. or a vehicle control injection.

190 cted with TNF (5 mug/mouse for 3-6 hours) or vehicle (control); intestines were collected and analyze

191 crease in capillary density by comparison to vehicle control, intramuscular vs. oral administration o

192 hey received either a dorsal CA3 lesion or a vehicle control lesion.

193 led cells was not significantly changed from vehicle control levels following either acute (1, 3, 10,

194 TAC and maintained miR-133a expression near vehicle control levels, which coincided with (1) a decre

195 d the median survival to 163 d compared with vehicle controls (log-rank test, p = 0.0001), in contras

196 Rats received vehicle (controls), lovastatin (30 mg/kg), or atorvastat

197 processing the Ag, pigeon cytochrome c, than vehicle control macrophages.

198 icient mice administered P(4) was similar to vehicle control mice and significantly reduced compared

199 cient mice administered P(4) were similar to vehicle control mice and the latency to immobility was s

200 All vehicle control mice established HCV infection, reaching

201 d a similar number of central entries as did vehicle control mice, both were lower than central entri

202 ar old) cynomolgus monkeys were given either vehicle control (n = 1) or TAM (n = 3) twice daily for a

203 ed with the complement inhibitor CR2-Crry or vehicle control (n=6).

204 Although no changes were observed in the vehicle controls (n = 5), chronic infusions of 7.5 micro

205 /kg intravenously, n = 9) or isotonic saline vehicle (control, n = 5) administration, liver samples w

206 2 mug (g body weight)(-1) day(-1), n = 7) or vehicle (control, n = 9) were infused in pregnant C57/BL

207 were treated with CP-690,550 (n = 18) or its vehicle (controls, n = 3) and were euthanized at day 90

208 pharmacologically lesion the 5-HT system, or vehicle (control; n = 14).

209 de [LPS], 3 mg/ kg, intravenously; n = 9) or vehicle (control; n = 5) treatment, ileal segments were

210 tumor volumes were injected s.c. daily with vehicle (control; n = 6), fulvestrant (1 mg/d; n = 7), l

211 Treatment groups received isotonic saline vehicle (control; n = 6), lipopolysaccharide (3.0 mg/kg,

212 Following isotonic saline vehicle (control; n = 6), lipopolysaccharide (3.0 mg/kg,

213 ats were divided into four treatment groups: vehicle-control, noise-only, CAE-only and CAE+noise.

214 1 hour before induction of inflammation), or vehicle control on acute inflammation in an air-pouch mo

215 1 mice were treated with BPA (5 mg/kg IP) or vehicle control on d 9-16 of pregnancy.

216 reduced EtOH responding by as much as 97% of vehicle control on day 1.

217 Cultures of TM cells were treated with vehicle control or latanoprost acid for 24 hours.

218 CBSM cell cultures were treated with vehicle control or latanoprost acid for 24 hours.

219 iven MI and animals were treated either with vehicle control or p1158/59 matricryptin.

220 were cultured for 7 days, after which either vehicle control or SSRI (10(-6) mol/L) was added for 2 h

221 ltured in the presence of interleukin-2 with vehicle control or the SSRI (10(-6) mol/L) for 2 hours.

222 high-fat diet were orally administered with vehicle control or UFP (40 mug/mouse/day) for 3 days a w

223 ovarian tumors developed in 86 rats used as vehicle controls or that received DEN alone or TCDD alon

224 eceived intra-articular injections of Ringer vehicle (control) or an activator of classical PKC isofo

225 ley rats 3 weeks after treatment with either vehicle (control) or streptozotocin (diabetic).

226 and treated with dimethyl sulfoxide (DMSO) (vehicle control) or with the PI3K inhibitor LY294002 or

227 erwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg

228 oups included (a) 1% anecortave acetate, (b) vehicle control, or (c) no treatment.

229 road salt (200 or 1000 mg Cl(-)/L), ethanol-vehicle control, or no-stressor control) and subsequentl

230 To test the hypothesis, vehicle control- or TCDD-treated mice were intranasally

231 ith 100 mug/kg beta-estradiol 17-valerate or vehicle (control) over 7 and 28 days.

232 a K1-negative strain or to treatment with a vehicle control (P < 0.0001).

233 omycin alone, and 58% (95% CI, 50 to 67) for vehicle control (P<0.001 for each treatment group vs. th

234 s post TAC, respectively, when compared with vehicle control (P<0.05).

235 mean 92.2% (range, 86.0%-99.4%) reduction vs vehicle controls (P < .0001) and in prolonged animal sur

236 by 34% (iv) and 14% (IP) in comparison with vehicle controls (p < .05 for iv treatment).

237 rk (37 +/- 8.3%) of treated eyes relative to vehicle controls (p < 0.005; 5 muM Lat-B).

238 etinal fluid reabsorption when compared with vehicle controls (P < 0.05; repeated measures ANOVA).

239 macrophages/activated microglia compared to vehicle controls (p<0.025); however, these changes in th

240 Compared with vehicle controls, paricalcitol significantly attenuated

241 Compared with vehicle controls, PF-04178903-treated mice demonstrated

242 mice with orthotopic cecal tumors were given vehicle (controls), PGE2, celecoxib, and/or Ono-AE3-208.

243 ive, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies.

244 We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments c

245 Compared with vehicle controls, PHY administration significantly incre

246 Control rats were given vehicle (control plus saline, 2 mL/kg bolus injection, f

247 CAI (100 mg/kg) or vehicle control polyethylene glycol-400 (PEG-400) was gi

248 xenografted with ATLL cells and treated with vehicle control, PS-341, Zol, or a combination of PS-341

249 rom all three treatment groups and also from vehicle control rats on day six, following five consecut

250 molality by approximately 2-fold compared to vehicle control rats, even under conditions of maximum a

251 earning (inhibitory avoidance) compared with vehicle control rats.

252 Unlike (vehicle) control rats, SH induced a significant pLTF in

253 Compared to vehicle controls, rats receiving lower and mid-range dos

254 tion, whereas 100% of the mice receiving the vehicle control remained normoglycemic.

255 The vehicle control requirements are quantified with respect

256 microg/kg of recombinant human (rh) IL-10 or vehicle control shortly before receiving intramuscular p

257 Treatment with CCPA compared with saline vehicle (control) significantly reduced infarct size, ex

258 ncreased in (+)-JQ1 treated mice compared to vehicle control, similar to the original study.

259 Compared with vehicle controls, slices pre-incubated 60 min in the pre

260 ontrols; hydrochloric acid aspiration alone; vehicle control solution followed 24 hrs later by mechan

261 pproved drug FTY720 (fingolimod, Gilenya) or vehicle control solution from 5 months of age.

262 of the vav promoter were administered G6 or vehicle control solution, and efficacy was determined by

263 groups (SRP plus subgingival application of vehicle control [SRP + V], or SRP plus subgingival appli

264 5 (64.1%) and 15 (36.6%), respectively, were vehicle-controlled studies.

265 Microinjections into the PnO of saline (vehicle control), the GABA(A) receptor agonist muscimol,

266 e for 24 hours following pretreatment with a vehicle control, the cysteine biosynthesis inhibitor pro

267 Compared to vehicle controls there was a significant reduction in sp

268 from 0.02 to 1.4 endotoxin units (EUs) or a vehicle control to both eyes.

269 untreated control group in addition to DMSO vehicle control to check for solvent toxicity.

270 creased in the TCDD-treated mice relative to vehicle control-treated mice.

271 nal cell carcinoma cells did not differ from vehicle control treatment, similar to the original study

272 l as long-term spatial memory, compared with vehicle control treatment.

273 Compared with the saline (vehicle) control treatment, prenatal dexamethasone signi

274 scular endothelial growth factor receptor or vehicle-control treatment (10 per group) in HaCaT-ras A-

275 We demonstrated that, in comparison to vehicle-control treatment, one of the brain-targeted pol

276 cetin-3-O-glucuronide treatment, compared to vehicle-control treatment, significantly improved AD-typ

277 compared with a 1 g/kg dose, and 0.15 M NaCl vehicle control treatments.

278 We conducted a randomized, double-blind, vehicle-controlled trial to assess the efficacy of resiq

279 dlPFC-dependent task performance relative to vehicle control values (group young OVX+Veh) but nonethe

280 ng performance over a 30-min delay to 27% of vehicle controls values.

281 clate in bioabsorbable vehicle (DHV) or with vehicle control (VC) in vivo.

282 phonate (zoledronate [Zol]), PTH, or saline (vehicle control [VC]) was administered for 10 days (n =

283 A tube of topical ivermectin or vehicle control was dispensed on day 1, to be applied to

284 A DMSO or PBS vehicle control was included for each experiment based o

285 ALN, parathyroid hormone (PTH), or saline (vehicle control) was administered.

286 lasty with local delivery of RvD2 (10 nM vs. vehicle control) was employed to examine effects on vasc

287 d to 1 mM PTU (EC(50)=0.88 mM), 1 mM MMI, or vehicle control (water) from stages 2 to 45.

288 e administration of either corticosterone or vehicle control, we tested the birds' responses to the c

289 receiving ivermectin than patients receiving vehicle control were louse-free on day 2 (94.9% vs. 31.3

290 ne (MCF-7) treated with 17-beta-estradiol or vehicle control were used to develop a mass-action kinet

291 8 nanocrystals (30 and 60 mg/kg body wt) and vehicle controls were injected i.p. immediately after I/

292 the 5-HT4R antagonist GR113808 (1 mg/kg), or vehicle (control) were delivered by enema to wild-type o

293 ter in the PQQ-treated group compared to the vehicle controls when PQQ was given at 10 and 3 mg/kg, b

294 lofilium in 12 of 14 rabbits pretreated with vehicle control, whereas pretreatment with W-7 (50 micro

295 tly reduced conditioned defeat compared with vehicle controls, whereas the CRF-sub-1 receptor antagon

296 randomly assigned to one of five groups: a) vehicle controls, which received saline intraperitoneall

297 eated CD18-deficient PL/J mice compared with vehicle controls, which was associated with decreased CD

298 alled WR 279,396), 15% paromomycin alone, or vehicle control (with the same base as the other two cre

299 f the atrial refractory period compared with vehicle controls without affecting the ventricular refra

300 ited liver tumor burden by 95% compared with vehicle control, without any observable signs of toxicit